Trimipramine
| Trimipramine | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 294.40 g/mol [1] |
| Melting point | 45 °C [1] |
| Solubility | Slightly soluble [1] |
| Predicted LogP | 5.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C20H26N2 |
| IUPAC name | 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine |
| SMILES | CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C |
| InChI | InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3 |
| InChIKey | ZSCDBOWYZJWBIY-UHFFFAOYSA-N |
| CAS number | 3564-75-8 |
| UNII | QJ9MUH57H8 |
| PubChem CID | 5584 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 23–24 hours |
| Metabolism | Hepatic |
| Excretion | Renal |
| Routes of administration | Oral, intramuscular injection, intravenous |
Trimipramine (also known as Trimeprimine, Trimeproprimine, Sapilent, β-Methylimipramine, Trimeprimina, Trimipramina, Trimipraminum, 7162 rp, Il 6001 or Il-6001) is a substance of the aniline class.
Chemistry
Stereochemistry []
Trimipramine is a racemic mixture of the enantiomers (optical activity ( + )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Trimipramine matches Lipinski's rule of five (violations: 1).Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- non-selective monoamine reuptake inhibitors (N06AA)
- trimipramine (N06AA06)
MeSH Classification
Mechanism of action []
Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT). [1]
Interactions []
Medical side effects []
86 side effects listed on drug labels in SIDER 4.1 (trimipramine).
- Abdominal pain
- Lymphadenitis
- Agranulocytosis
- Alopecia
- Decreased appetite
- Anxiety
- Arrhythmia
- Asthenia
- Fatigue
- Ataxia
- Confusional state
- Feeling abnormal
- Malaise
- Constipation
- Libido decreased
- Disturbance in sexual arousal
- Delusion
- Diarrhoea
- Dizziness
- Somnolence
- Oedema
- Eosinophilia
- Dermatitis
- Rash
- Body temperature increased
- Flushing
- Gynaecomastia
- Hallucination
- Headache
- Atrioventricular block
- Hypertension
- Hypotension
- Inappropriate antidiuretic hormone secretion
- Jaundice
- Mydriasis
- Myocardial infarction
- Acute coronary syndrome
- Nausea
- Nightmare
- Hypoaesthesia
- Sensory loss
- Palpitations
- Ileus paralytic
- Neuropathy peripheral
- Petechiae
- Pruritus
- Psychotic disorder
- Purpura
- Vascular purpura
- Convulsion
- Stomatitis
- Cerebrovascular accident
- Tachycardia
- Thrombocytopenia
- Tinnitus
- Tremor
- Pollakiuria
- Urticaria
- Vomiting
- Weight increased
- Dry mouth
- Urinary retention
- Agitation
- Drug withdrawal syndrome
- Pancytopenia
- Accommodation disorder
- Dyspepsia
- Discomfort
- Ill-defined disorder
- Disorientation
- Extrapyramidal disorder
- Dysgeusia
- Tongue discolouration
- Galactorrhoea
- Paraesthesia
- Tingling sensation
- Hypomania
- Erectile dysfunction
- Oropharyngeal discomfort
- Oropharyngeal pain
- Vision blurred
- Parotid gland enlargement
- Coordination abnormal
- Insomnia
- Breast enlargement
- Testicular swelling
Indications
- Depressive symptom
- Endogenous depression
Subjective effects []
| emily / Trimipramine [] | |
|---|---|
Routes:
| |
Legal status []
- Australia: Trimipramine is a Schedule 4.
- Brazil: Trimipramine is a C1.[3]
- Canada: Trimipramine is Prescription only.
- United Kingdom: Trimipramine is Prescription only.
- United States: Trimipramine is Prescription only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5584, Trimipramine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5584
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Trimipramine. UNII: QJ9MUH57H8. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/QJ9MUH57H8
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 10:31:10 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 10:31:06 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:31:06 |
| gsrs | ok | 2026-11-20 10:31:06 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014864) | 2026-11-20 10:31:06 |
| kegg | ok | 2026-11-20 10:31:09 |
| pubchem | ok | 2026-11-20 10:31:04 |
| missing (no r/tripreports posts mention it) | 2026-11-20 10:31:06 | |
| sider | ok | 2026-11-20 10:31:06 |
| structure | ok | 2026-11-20 10:31:06 |
| wikipedia | ok | 2026-11-20 10:31:06 |